0K1R.LSE Viridian Therapeutics Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -70.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0K1R.LSE undervalued?
Graham numberThe Graham number of Viridian Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Viridian Therapeutics Inc. fundamental analysis
No fundamental analysis for Viridian Therapeutics Inc. yet.
Viridian Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Viridian Therapeutics Inc.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatme…
Full company profileViridian Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Viridian Therapeutics Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.48M | 4.00M | 8.39M | 4.46M | 1.05M | 2.96M | 1.77M | 314K | 302K | 70.8M | 850K |
| Gross Profit | 929K | -15.6M | -22.0M | -28.3M | -27.3M | 2.34M | 1.02M | -159M | -938K | 69.7M | 374K |
| Operating Income | -17.0M | -26.5M | -33.1M | -42.0M | -40.2M | -79.7M | -134M | -254M | -299M | -363M | -485M |
| EBITDA | -16.6M | -26.2M | -31.5M | -39.7M | -110M | -78.8M | -129M | -254M | -266M | -362M | -485M |
| Net Income | -17.3M | -26.5M | -32.7M | -41.9M | -111M | -79.4M | -130M | -238M | -209M | -343M | -464M |
| EPS | -423 | -21 | -17 | -20 | -31 | -6.66 | -4.05 | -5.31 | -3.07 | -4.04 | -4.30 |
| Balance Sheet | |||||||||||
| Total Assets | 24.8M | 52.5M | 66.1M | 30.3M | 131M | 204M | 435M | 490M | 742M | 899M | 1.10B |
| Total Liabilities | 9.71M | 14.0M | 14.8M | 14.5M | 11.2M | 16.0M | 40.0M | 48.4M | 70.8M | 177M | 435M |
| Shareholders' Equity | 15.1M | 38.5M | 51.3M | 15.8M | 120M | 188M | 395M | 442M | 672M | 722M | 662M |
| Cash & Short-term Investments | 22.1M | 47.4M | 62.5M | 26.8M | 128M | 197M | 425M | 477M | 718M | 875M | 982M |
| Total Debt | 4.79M | 9.92M | 10.3M | 8.30M | 498K | 1.04M | 6.36M | 22.0M | 23.1M | 52.6M | 243M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -14.8M | -28.2M | -26.8M | -36.1M | -29.8M | -54.6M | -93.8M | -184M | -232M | -277M | -450M |
| Capital Expenditure | 250K | 246K | 445K | 84.0K | 42.0K | 338K | 797K | 898K | 511K | 495K | 2.66M |
| Free Cash Flow | -15.0M | -28.4M | -27.3M | -36.1M | -29.8M | -54.9M | -94.6M | -185M | -233M | -277M | -453M |
| Ratios | |||||||||||
| ROE | -115.1% | -68.9% | -63.7% | -265.8% | -92.2% | -42.3% | -32.9% | -53.8% | -31.1% | -47.4% | -70.1% |
| ROA | -70.0% | -50.5% | -49.4% | -138.4% | -84.4% | -39.0% | -29.8% | -48.5% | -28.1% | -38.1% | -42.3% |
| Net Profit Margin | -498.2% | -662.4% | -390.0% | -938.6% | -10,544.3% | -2,680.2% | -7,329.2% | -75,711.5% | -69,059.6% | -483.6% | -54,592.9% |
| Debt to Equity | 0.32x | 0.26x | 0.20x | 0.53x | 0.00x | 0.01x | 0.02x | 0.05x | 0.03x | 0.07x | 0.37x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Viridian Therapeutics Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 44.0K | 0.01 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 0.066667:1 on Nov 13, 2020.
Who owns Viridian Therapeutics Inc.
- Insiders 0.17%
- Institutions 99.83%
- Public & others 0.00%
- Free float 101M
Viridian Therapeutics Inc. company profile
- Company name
- Viridian Therapeutics Inc.
- Ticker
- 0K1R.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 252
- Fiscal year end
- December
- Address
- 221 Crescent Street, Waltham, MA, United States, 02453
- Phone
- 617 272 4600
- Website
- viridiantherapeutics.com
About Viridian Therapeutics Inc.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Viridian Therapeutics Inc. management
10- Mr. Stephen F. Mahoney J.D., MBACEO, President & Director · born 1971
- Mr. Seth HarmonChief Financial Officer · born 1981
- Mr. Thomas W. Beetham J.D., MBAChief Operating Officer · born 1970
- Ms. Jennifer Tousignant J.D.Chief Legal Officer & Corporate Secretary · born 1973
- Dr. Radhika Tripuraneni M.D., M.P.H.Chief Medical Officer · born 1980
- Dr. Eric N. Olson Ph.D.Co-Founder & Chairman of Scientific Advisory Board
- Dr. Michael R. Bristow M.D., Ph.D.Co-Founder & Member of the Scientific Advisory Board · born 1945
- Dr. Marvin H. Caruthers Ph.D.Co-Founder & Scientific Advisory Board Member · born 1940
- Mr. Vahe Bedian Ph.D.Co-Founder & Scientific Advisor
- Ms. Melissa MannoChief Human Resources Officer